Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.670
-0.030 (-1.76%)
At close: Jun 3, 2026, 4:00 PM EDT
1.662
-0.008 (-0.50%)
After-hours: Jun 3, 2026, 4:55 PM EDT

Inhibikase Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
49.57139.2256.499.177.1940.75
Short-Term Investments
120.839.5441.054.0915.86-
Cash & Short-Term Investments
170.37178.7697.5413.2523.0540.75
Cash Growth
82.84%83.27%636.06%-42.51%-43.44%192.04%
Accounts Receivable
----0.040.11
Other Current Assets
1.811.350.910.961.281.61
Total Current Assets
172.18180.1198.4514.2124.3742.47
Net Property, Plant & Equipment
--0.150.30.57-
Other Long-Term Assets
1.161.1----
Total Assets
173.33181.2198.614.5124.9442.47
Accounts Payable
1.591.160.940.651.151.09
Accrued Expenses
4.124.082.682.262.42.72
Short-Term Debt
---0.38-0.25
Current Portion of Leases
--0.110.150.15-
Other Current Liabilities
-3.06----
Total Current Liabilities
5.718.33.733.443.74.05
Long-Term Leases
---0.090.21-
Total Long-Term Liabilities
---0.090.21-
Total Liabilities
5.718.33.733.533.94.05
Common Stock
0.130.130.070.0100.03
Additional Paid-in Capital
326.58315.43189.2677.8768.868.21
Accumulated Other Comprehensive Income
-0.030.02-0.0400.1-
Retained Earnings
-159.06-142.68-94.42-66.9-47.87-29.82
Shareholders' Equity
167.62172.994.8710.9821.0438.42
Total Liabilities & Equity
173.33181.2198.614.5124.9442.47
Total Debt
-00.110.620.350.25
Net Cash (Debt)
170.37178.7697.4312.6322.740.5
Net Cash Growth
-4.70%83.47%671.44%-44.36%-43.95%197.05%
Net Cash Per Share
1.431.824.112.105.3813.35
Book Value
167.62172.994.8710.9821.0438.42
Book Value Per Share
1.411.764.001.824.9812.66
Tangible Book Value
167.62172.994.8710.9821.0438.42
Tangible Book Value Per Share
1.411.764.001.824.9812.66
SEC Filings: 10-K · 10-Q